Page 66 - HPV e 100 domande

MAGAGGIOGRINOA2M0E1N8TO:

Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against
HPV infection and disease in males. N Eng J Med 2011;364: 401-11.

Grimaldi-Bensouda L, Rossignol M, Kont I. Risk of autoimmune diseases and human papillo-
ma virus (HPV) vaccines: Six years of case-referent surveillance. Journal of Autoimmunity
2017;79:84-90. doi: 10.1016/j.jaut.2017.01.005. Epub 2017 Feb 9.

Harper DM, DeMars LR. A review of the first decade. Gynecol Oncol 2017;146(1):196-204.
doi: 10.1016/j.ygyno.2017.04.004. Epub 2017 Apr 22.

Hildesheim A, Gonzalez P,mWacholder S et al; Costa Rica HPV Vaccine TriaCVT)GroupIm-
pact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and
rates of cervical lesions after excisional treatment. Am J Obstet Gynecol 2016;215(2):212.
e1-212.e15. doi: 10.1016/j.ajog.2016.02.021. Epub 2016 Feb 16.

Huh WK, Giuliano AR, Iversen OE et al. Final efficacy, immunogenicity, and safety analyses
of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised,
double-blind trial. Lancet 2017;390(10108):2143-59.

Joura EA, Garland SM, Paavonen J et al.; for the FUTURE I and II Study Group. Effect of the
human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical
and vulvar disease: retrospective pooled analysis of trial data BMJ 2012;344:e1401 (pub-
lished 27 March 2012).

Joura EA, Giuliano AR, Iversen OE et al. A 9-valent HPV vaccine against infection and intraep-
ithelial neoplasia in women. N Engl J Med 2015;372:711-23.

Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after Loop Elec-
trosurgical Excision procedure effective in preventing recurrence in patients with high-
grade cervical intraepithelial neoplasia (CIN2-3). Gynecol Oncol 2013. doi:10.1016/j.
gyno.2013.04.050 (epub ahead of print).

Kim JJ. Weighing the benefits and costs of HPV vaccination of young men. N Eng J Med
2011;364: 393-95.

Kjaer SK, Nygård M, Dillner J et al. A 12-Year Follow-up on the Long-Term Effectiveness of the
Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Clin Infect Dis 2018;66(3):339-345.
doi: 10.1093/cid/cix797.

Lehtinen M, Lagheden C2, Luostarinen T et al. Ten-year follow-up of human papillomavirus
vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based
follow-up of three cohorts from randomized trials. BMJ Open 2017;7(8):e015867. doi:
10.1136/bmjopen-2017-015867.

Malagon T, Drolet M, Boily MC et al. Cross-protective efficacy of two human papillomavirus
vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:781-89.

Munoz N, Monalastas R, Pitisuttithum P et al. Safety, immunogenicity, and efficacy of quadri-
valent human papillomavirus (types 6,11,16,18) recombinant vaccine in women aged 24-45
years: a randomised, double-blind trial. Lancet 2009;373:1949-57.

Naud PS Roteli-Martins CM, De Carvalho NS et al. Sustained efficacy, immunogenicity, and
safety of the HPV-16/18AS04-adjuvanted vaccine: final analysis of a long-term follow-up
study up to9.4 years post-vaccination. Hum Vaccin Immunother 2014;10(8):2147-62.

Nygård M, Saah A, Munk C Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6),
11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine. Clin Vac-
cine Immunol 22:943-48. doi:10.1128 /CVI.00133-15.

Le 100 DOMANDE sull’HPV
64 Informazioni per gli operatori